x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:10:45

Barclays Miami: Ocular Therapeutix's Chair Pravin...

BiotechTV - News ·

2026/03/11

He gives his take on two questions being discussed the most: 1) is AXPAXLI approvable on one study and 2) how might physicians think about using it in practice.

en-us

00:13:10

Barclays Miami: Xencor CEO Bassil Dahiyat discusses...

BiotechTV - News ·

2026/03/11

He highlights pipeline programs targeting ENPP3, CLDN6, CLDN18.2, TL1A (including TL1A x IL23p19), CD20 x CD3, and CD19xCD3.

en-us

00:13:58

Barclays Miami: Recludix believes the time is right...

BiotechTV - News ·

2026/03/10

President & CEO Nancy Whiting discusses the historical difficulties in drugging SH2, and describes the company's discovery platform that enables it today. A STAT6 program is already dosing in the clinic, and Sanofi has a partnership on it. Plus, a BTK, and a recent financing that Lilly participated in.

en-us

00:11:16

Barclays Miami: Barclays' Senior Biotech Analyst...

BiotechTV - News ·

2026/03/10

She discusses uniQure, Moderna, BridgeBio, Gossamer Bio and more.

en-us

00:11:03

Barclays Miami: Janux's Founder & CEO David Campbell...

BiotechTV - News ·

2026/03/10

He shares highlights from data announced at the end of the year, and what Janux has learned about the program's dosing and safety mitigation profile. Also, why he has his sights set on the FcRn market when he thinks about the company's CD19.

en-us

00:09:20

Barclays Miami: Teva CEO Richard Francis talks about...

BiotechTV - News ·

2026/03/10

He discusses the company's third year in a row of revenue growth, and the new products that have helped Teva get there. Plus, a potential near-term approval for a monthly dosed schizophrenia product, and the lates on IL-15 and TL1A.

en-us

00:07:34

Barclays Miami: Latigo Bio aims to have a...

BiotechTV - News ·

2026/03/10

CEO Nima Farzan explains the science behind Nav1.8, why he believes Latigo's asset could be best in class, and the status of the company's development program.

en-us

00:08:10

Barclays Miami: Arvinas will have an update next week...

BiotechTV - News ·

2026/03/10

Randy Teel updates us on effectors to find a commercialization partner for the ER degrading PROTAC that is in front of FDA right now with a June 5 decision date scheduled. Plus, discussing programs targeting KRAS, BCL6, polyQ-AR and more.

en-us

00:06:13

Barclays Miami: Electra Therapeutics has taken a...

BiotechTV - News ·

2026/03/10

President and CEO Kathy Dong describes the function of SIRPs and how Electra is targeting them with antibodies. Plus, an overview of the company's privotal program against secondary Hemophagocytic Lymphohistiocytosis (sHLH).

en-us

00:05:55

Barclays Miami: enGene is looking to have pivotal...

BiotechTV - News ·

2026/03/10

CEO Ron Cooper describes why you need an alternative to virally delivered products for indications like bladder cancer. Plus, previewing a data update in the spring and 12 month data by the end of the year.

en-us

00:08:13

Barclays Miami: Barclays' Chair and Co-Head of Global...

BiotechTV - News ·

2026/03/10

He believes that the sector's fundamentals are strong and that M&A, which played a central role in boosting biotech last year, can keep up in 2026. Plus, he believes there is a good supply of quality IPOs in the queue that can meet demand that has been there for a while.

en-us

00:23:31

Quell Tx believes that restoring immune balance...

BiotechTV - News ·

2026/03/03

CEO Iain McGill describes the "Chill, not Kill" approach that Quell is taking with its Treg platform, which integrates a FOXP3 phenotype lock in addition to the CAR. Plus, an update on the company's liver transplant study, a program that he says will need a partner to move forward.

en-us

00:25:56

Protagonist Therapeutics has two medicines in front...

BiotechTV - News ·

2026/02/20

CEO Dinesh Patel and Chief Discovery Officer Ashok Bhandari walk us through the company's R&D expertise, and we discuss programs covering IL-23, IL-17, a hepcidin mimetic, and obesity medicines.

en-us

00:25:30

Cambridge, UK based Arecor uses formulation and...

BiotechTV - News ·

2026/02/19

CEO Sarah Howell discusses three key aspects of the business: helping with reformulation, its own proprietary insulin products, and developing oral peptides like GLPs.

en-us

00:11:24

NewLimit is using epigenetic reprogramming to bring...

BiotechTV - News ·

2026/02/19

Co-Founder & President Jacob Kimmel describes the science behind how this works, and the enormous amount of work that goes into choosing which transcription factors to target. The company is currently in IND enabling studies.

en-us

00:10:14

Gordian Biotechnology announced that it will be using...

BiotechTV - News ·

2026/02/18

Co-Founder & CSO Martin Borch Jensen describes the deal and walks us through Gordian's process that enables it to do a multiplicity of in vivo screening in months that previously would have taken years.

en-us

00:11:45

Cambridge, UK based Microbiotica announced results...

BiotechTV - News ·

2026/02/18

CEO Tim Sharpington and CMO Robert Tansley walk us through the treatment, which contains a defined consortium of eight live gut commensal bacterial strains, and the data.

en-us

00:13:20

Ocular Therapeutix Chair & CEO Pravin Dugel discusses...

BiotechTV - News ·

2026/02/17

The study showed that AXPAXLI has superior maintenance of visual acuity at Week 36 vs EYLEA. Dr. Dugel discusses what he believes the significance of this is, and delves into durability data going out to 52 weeks.

en-us

00:15:35

Oxford based Infinitopes raised an additional $15.4M...

BiotechTV - News ·

2026/02/17

Co-Founder & CEO Jonathan Kwok describes the company's platform, which helps it identify highly expressed and immunogenic tumor antigens, and how the lead program for oesophageal cancer will have data by the end of 2026.

en-us

00:09:35

From Oxford: Carlo Rinaldi's team has received two...

BiotechTV - News ·

2026/02/17

He describes his work in these diseases and how Oxford-Harrington has provided funding and advice that has been valuable beyond the feedback he typically receives in an academic setting.

en-us

408 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter